Bronchoscopy With Bronchial Biopsies Sub-study of: Persistence of Airway Inflammation and Remodeling in Asthma Remission
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study aims at determining the patterns of asthma remission, the prevalence of these different patterns and the various factors associated with such remissions and possible recurrences of asthma, in order to determine the mechanisms involved in these processes.
We therefore want to document these specificities in studying biopsies of subjects in complete remission of their asthma and those in only symptomatic remission of their asthma, in comparison with mildly symptomatic asthmatic subjects and healthy controls.
| Condition |
|---|
|
Asthma |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Cross-Sectional |
| Official Title: | Bronchoscopy and Bronchial Biopsies. Sub-study of: Characteristics of Asthma Remissions |
Tissue (bronchial biopsies)
| Estimated Enrollment: | 36 |
| Study Start Date: | September 2007 |
| Estimated Study Completion Date: | March 2011 |
| Groups/Cohorts |
|---|
|
1
Subjects with complete remission of asthma
|
|
2
Subjects with symptomatic remission of asthma
|
|
3
Subjects with asthma
|
|
4
Healthy controls
|
Detailed Description:
Primary Outcome Measures :
Airway inflammation and remodeling: in bronchial biopsies
Secondary Outcome Measures:
Comparisons of bronchial biopsy features between groups:
- Bronchial epithelial morphology
- Bronchial mucosa (smooth muscle, reticular basement membrane, submucosal gland,...)
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Subjects with current asthma or in remission of asthma from primary care clinics will be allowed to participate to this study. Healthy subjects will also be invited by advertisements in newspapers to volunteer for this study.
Inclusion Criteria:
- In remission of their asthma: absence of respiratory symptoms, no rescue asthma medication need and (for complete remission) an optimal pulmonary function (FEV1 > 90%) and normal PC20 methacholine for more than two years (with no current treatment).
- With a proven past history of asthma from medical files (reversible airway obstruction (> 12% FEV1 after bronchodilator or 20% by other means) proven by spirometry, PEF measures or methacholine challenge according to current criteria + previous symptoms and asthma medication use), having no more asthma symptoms and not having used asthma medication for more than 2 years.
- Agree to sign the consent form.
- No other condition that could interfere with the study measurements.
Exclusion Criteria:
- Subjects using inhaled or oral anti-inflammatory agents.
- FEV1 < 1.2 L.
- Unable to adhere to the protocol requirements.
- Other current respiratory disease
- Upper or lower respiratory tract infection or use of antibiotics < 1 month.
- Use of oral corticosteroids within the last 3 months.
- Signs or symptoms of progressive or uncontrolled renal, hepatic, hematologic, endocrine, pulmonary, cardiac, neurologic or cerebral disease.
Contacts and Locations
More Information
No publications provided
| Responsible Party: | Louis-Philippe Boulet, Laval Hospital |
| ClinicalTrials.gov Identifier: | NCT00526344 History of Changes |
| Other Study ID Numbers: | HL-07- sep-biop |
| Study First Received: | September 5, 2007 |
| Last Updated: | February 10, 2011 |
| Health Authority: | Canada: Canadian Institutes of Health Research |
Keywords provided by Laval University:
|
remission of asthma |
Additional relevant MeSH terms:
|
Asthma Bronchial Diseases Respiratory Tract Diseases Lung Diseases, Obstructive Lung Diseases |
Respiratory Hypersensitivity Hypersensitivity, Immediate Hypersensitivity Immune System Diseases |
ClinicalTrials.gov processed this record on May 22, 2013